ADME

ADME organizes a substance's pharmacokinetic fate as route-conditioned absorption, distribution, metabolism and excretion.

Version

v1 · 2026-10-31 · History

Domain-specific #

14459

Domain group

Applied Sciences & Engineering

Origin domain

Pharmacology & Toxicology

Subdomain

Drug Disposition → Pharmacology & Toxicology

Aliases

Absorption Distribution Metabolism Excretion

Core Idea

ADME organizes the pharmacokinetic fate of a substance as absorption, distribution, metabolism and excretion. These are distinct investigative questions, not four mandatory consecutive phases. Intravenous administration bypasses extravascular absorption, while movement, transformation and removal can overlap.^[1][2]

How would you explain it like I'm…

The Medicine's Journey

When you take medicine, grown-ups who study medicines ask four questions about it. How does it get into your blood? Where in your body does it go? What does your body change it into? How does it leave your body? These things don't have to happen one after another like a line; some can happen at the same time.

Four Medicine Questions

ADME stands for absorption, distribution, metabolism and excretion. Scientists use these four words as questions about any medicine or chemical that goes into a body. How does it get into the bloodstream, where does it spread, what does the body turn it into, and how do the medicine and its leftovers get out? The questions are not a line of steps in order — the body can be spreading, changing and removing a drug all at once. And a shot straight into a vein skips the getting-in question entirely.

Absorption to Excretion Frame

ADME — absorption, distribution, metabolism, excretion — is a framework pharmacologists use to organize what happens to a substance after it is given to an organism. Absorption asks how it reaches the general circulation; distribution asks where the original compound and its products end up; metabolism asks what new molecules the body makes from it; excretion asks how they leave. It is a set of questions, not an assembly line: these processes overlap in time, and an intravenous dose bypasses absorption across a barrier. It also matters which molecule you track: when the body turns a drug into another chemical that leaves in urine, that is not the same as the original drug leaving unchanged. A single measurement of drug level in the blood over time cannot answer all four questions at once.

 

ADME (absorption, distribution, metabolism, excretion) is the organizing frame of pharmacokinetics: four questions about the fate of an administered substance in an organism. Absorption asks how the compound reaches systemic circulation; distribution asks where the parent compound and its products go; metabolism asks which molecules are produced by biotransformation; excretion asks how parent and metabolites leave the body. These processes are not sequential stages — distribution, transformation and elimination proceed concurrently over time, and intravenous dosing bypasses extravascular absorption entirely. Regulatory pharmacokinetic descriptions keep the questions separate because a single plasma concentration–time curve cannot identify all of them. The analyte must also be specified: midazolam, for example, is converted by CYP3A4 to hydroxylated products and eliminated mainly as urinary conjugates, with very little unchanged drug recovered in urine. Talking about 'the drug's clearance' without naming the measured species can hide the actual mechanism.

Scope of Application

The FDA's 2018 Seizalam midazolam label reports after a 10 mg IM dose a median time to plasma peak of 0.5 hours, approximately 97% plasma-protein binding, CYP3A4-mediated hydroxylation and urinary elimination mainly as conjugated metabolites. This is a documented product case, not current prescribing advice. The EMA's 2020 Veklury assessment instead concerns IV remdesivir: it peaks at infusion end, is reported as 88–93.6% protein bound in the FDA’s 2024 label, undergoes intracellular metabolic activation and yields urine recovery mainly as GS-441524.^[3][1][2]

Clarity

Absorption asks how an extravascular dose reaches systemic blood; distribution asks where measured parent or products partition; metabolism asks what chemicals are formed; excretion asks which species leave. A falling parent concentration can reflect both distribution and metabolism, not necessarily unchanged-parent excretion. Midazolam's urinary products are mostly conjugates, while less than 0.5% unchanged parent was recovered in urine after a separate IV dose.^[3]

Manages Complexity

The acronym is a compact checklist for missing evidence but can hide analyte- and route-specific mechanisms. In a midazolam ICU comparison, renal impairment was associated with accumulation of 1-hydroxy-midazolam glucuronide; this shows why parent-only measurements may miss metabolite exposure. The label says the link to prolonged sedation is unclear, so no clinical conclusion is inferred from that measurement here.^[3]

Abstract Reasoning

One can track administered mass through route-dependent entry, circulating and tissue compartments, transformed molecules and recovered products. The same measured parent decline does not uniquely identify each flow. In the EMA remdesivir account, parent and GS-441524 have very different terminal half-lives, illustrating why a rate must name its analyte.^[1][2]

Knowledge Transfer

ADME questions travel across substances, but numerical findings and the presence of an absorption barrier do not. The frame is domain-specific to pharmacokinetic fate in organisms, not a generic input–output metaphor. A general input–output metaphor omits the biological routes and chemically distinct species that determine pharmacokinetic fate.

Neighborhood in Abstraction Space

ADME sits in a sparse region of the domain-specific corpus (78^th percentile for distinctiveness): few abstractions share its structure, so a faithful description tends to retrieve it precisely.

Family — Drug Action & Receptor Pharmacology (17 abstractions)

Nearest neighbors

• First-Pass Metabolism — 0.86
• Absorption Phase — 0.84
• Injection (medicine) — 0.82
• Elimination Pathway — 0.82
• Clearance — 0.81

Computed from structural-signature embeddings · 2026-10-31

References

[1] European Medicines Agency. (2020). Veklury public assessment report. Pages 50–52; historical pharmacokinetic assessment, not current clinical instructions. registry ↩a ↩b ↩c

[2] U.S. Food and Drug Administration. (2024). Veklury prescribing information. Section 12.3 and Table 14; historical product data, not current clinical instructions. registry ↩a ↩b ↩c

[3] U.S. Food and Drug Administration. (2018). Seizalam midazolam injection prescribing information. Section 12.3; historical label notes it may not be current. registry ↩a ↩b ↩c